PLEUROPULMONARY CHANGES DURING TREATMENT OF PARKINSONS-DISEASE WITH A LONG-ACTING ERGOT DERIVATIVE, CABERGOLINE

被引：0
|
作者：
FRANS, E
DOM, R
DEMEDTS, M
机构：
[1] CATHOLIC UNIV HOSP,DEPT MED,DIV PULM,WELIGERVELD 1,B-3212 PELLENBERG,BELGIUM
[2] CATHOLIC UNIV HOSP,DEPT NEUROL,B-3212 PELLENBERG,BELGIUM
来源：
EUROPEAN RESPIRATORY JOURNAL | 1992年 / 5卷 / 02期
关键词：
CABERGOLINE; PLEUROPULMONARY CHANGE; PARKINSONS DISEASE;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with cabergoline, developed progressive pleuropulmonary abnormalities during the latter therapy. These lesions even worsened for some weeks after interruption of cabergoline, which may possibly be related to the prolonged action of this drug. Thus cabergoline may cause similar pleuropulmonary abnormalities to bromocriptine.
引用
收藏
页码：263 / 265
页数：3
相关论文
共 50 条
  • [1] CABERGOLINE - A LONG-ACTING DOPAMINE AGONIST IN PARKINSONS-DISEASE
    LERA, G
    VAAMONDE, J
    MURUZABAL, J
    OBESO, JA
    ANNALS OF NEUROLOGY, 1990, 28 (04) : 593 - 594
  • [2] FLUCTUATING PARKINSONS-DISEASE - TREATMENT WITH THE LONG-ACTING DOPAMINE AGONIST CABERGOLINE
    AHLSKOG, JE
    MUENTER, MD
    MARAGANORE, DM
    MATSUMOTO, JY
    LIEBERMAN, A
    WRIGHT, KF
    WHEELER, K
    ARCHIVES OF NEUROLOGY, 1994, 51 (12) : 1236 - 1241
  • [3] ERGOT DERIVATIVE IN TREATMENT OF PARKINSONS-DISEASE
    CALNE, DB
    KARTZINEL, R
    SHOULSON, I
    POSTGRADUATE MEDICAL JOURNAL, 1976, 52 : 81 - 82
  • [4] PLEUROPULMONARY CHANGES DURING LONG-TERM BROMOCRIPTINE TREATMENT FOR PARKINSONS-DISEASE
    LEWITT, PA
    CALNE, DB
    LANCET, 1981, 1 (8210): : 44 - 45
  • [5] LONG-TERM TOLERABILITY AND EFFICACY OF CABERGOLINE, A NEW LONG-ACTING DOPAMINE AGONIST, IN PARKINSONS-DISEASE
    INZELBERG, R
    NISIPEANU, P
    RABEY, MJ
    KORCZYN, AD
    MOVEMENT DISORDERS, 1995, 10 (05) : 604 - 607
  • [6] MULTICENTER STUDY OF CABERGOLINE, A LONG-ACTING DOPAMINE-RECEPTOR AGONIST, IN PARKINSONS-DISEASE PATIENTS WITH FLUCTUATING RESPONSES TO LEVODOPA CARBIDOPA
    LIEBERMAN, A
    IMKE, S
    MUENTER, M
    WHEELER, K
    AHLSKOG, JE
    MATSUMOTO, JY
    MARAGANORE, DM
    WRIGHT, KF
    SCHOENFELDER, J
    NEUROLOGY, 1993, 43 (10) : 1981 - 1984
  • [7] LONG-ACTING CARBIDOPA-LEVODOPA IN THE MANAGEMENT OF MODERATE AND ADVANCED PARKINSONS-DISEASE
    HUTTON, JT
    MORRIS, JL
    NEUROLOGY, 1992, 42 (01) : 51 - 56
  • [8] LONG TREATMENT IN PARKINSONS-DISEASE
    AUMAITRE, O
    CHICHE, JF
    ESCHALIER, A
    DORDAIN, G
    GAZETTE MEDICALE, 1985, 92 (37): : 87 - 90
  • [9] CABERGOLINE - LONG-ACTING ORAL TREATMENT OF HYPERPROLACTINEMIC DISORDERS
    FERRARI, C
    MATTEI, A
    MELIS, GB
    PARACCHI, A
    MURATORI, M
    FAGLIA, G
    SGHEDONI, D
    CROSIGNANI, PG
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 68 (06): : 1201 - 1206
  • [10] CABERGOLINE IN PARKINSONS-DISEASE - LONG-TERM FOLLOW-UP
    LERA, G
    VAAMONDE, J
    RODRIGUEZ, M
    OBESO, JA
    NEUROLOGY, 1993, 43 (12) : 2587 - 2590
12345